Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$403.8MCash on Hand
23.8mo Cash Runway
Follow LBRX by emailGet an email when LBRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LBRX, unsubscribe in one click. Privacy
📣 What LBRX Says Is Next
first quarter of 2028 · LB-102: “The Phase 2 ILLUMINATE-1 trial evaluating the efficacy and safety of LB-102 in patients with bipolar 1 depression continues to enroll patients, with topline data expected in the first quarter of 2028.”
Company press release, Nov 5, 2026 · SEC filing
first half of 2027 · LB-102: “Enrollment in the pivotal Phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 in patients with acute schizophrenia continues to progress strongly with topline data expected in the first half of 2027.”
Company press release, Nov 5, 2026 · SEC filing
early 2027 · “Initiation of the Phase 2 trial in the adjunctive treatment of MDD is expected in early 2027, with topline data expected in the first half of 2029.”
Company press release, Nov 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Earnings Reported Q3 2026 net loss of $59.1M versus $3.6M a year earlier, with R&D of $51.5M and cash of $403.8M as of Sept 30, 2026, expected to fund operations beyond Q2 2029. Phase 3 NOVA-2 topline data for LB-102 in schizophrenia is still expected in 1H 2027. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 1, 2026 ·
Financing LB Pharmaceuticals filed a shelf registration statement on Form S-3 covering offerings of common stock, preferred stock, debt securities, warrants and units, plus a sales agreement with TD Securities for up to $200,000,000 of common stock. Selling stockholders may also resell shares. Form S-3ASR · SEC filing
Sep 15, 2026 ·
Leadership Susan G. Kozauer, M.D. was appointed Chief Medical Officer effective September 14, 2026, with a $515,000 base salary, a 40% target bonus, a $150,000 sign-on bonus and an option to buy 200,000 shares, subject to board approval. Form 8-K · SEC filing · Press release
Sep 15, 2026 ·
Leadership LB Pharmaceuticals appointed Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026, with a $515,000 base salary, a 40% target bonus, a $150,000 sign-on bonus and an inducement option for 200,000 shares. Form 424B3 · SEC filing
Sep 3, 2026 ·
Leadership Appointed Joseph M. Miller as Chief Financial Officer effective September 2, 2026, at an annual base salary of $530,000 with a 40% target bonus and an inducement option for 200,000 shares. He previously served as CFO of Aurinia Pharmaceuticals. Form 8-K · SEC filing · Press release
Sep 3, 2026 ·
Leadership Appointed Joseph M. Miller as Chief Financial Officer effective September 2, 2026, with an annual base salary of $530,000, a 40% target bonus and an inducement option for 200,000 shares. Mr. Miller previously served as CFO of Aurinia Pharmaceuticals. Form 424B3 · SEC filing
Aug 11, 2026 ·
Earnings Reported Q2 2026 results: R&D expenses of $44.1 million versus $2.4 million a year earlier, G&A of $9.8 million, and a net loss of $51.6 million. Cash and marketable securities were $327.8 million as of June 30, 2026, excluding the $150.0 million July private placement. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2027 · Phase 3 · Recruiting · Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia Registry primary completion date, not a results date
Feb 2028 · Phase 2 · Recruiting · Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. Registry primary completion date, not a results date
Dec 2028 · Phase 3 · Recruiting · 52-week Open Label Safety-Tolerability Study Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
LBRX holds $403.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $51M/quarter from operations,
an estimated runway of 23.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:7 · Low
Cash runway 24 months +8
Company says cash lasts beyond the second quarter of 2029 -15Based on our current plans, we believe that our existing cash, cash equivalents and short-term investments will be sufficient to meet our anticipated operating and capital expenditure requirements beyond the second quarter of 2029.10-Q, Nov 2026
Share count 32,363,040 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full LBRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LBRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.